{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T04:26:49Z","timestamp":1768451209767,"version":"3.49.0"},"reference-count":48,"publisher":"The Endocrine Society","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,7,1]]},"abstract":"<jats:p>Currently, there are no reliably effective therapeutic options for metastatic pheochromocytoma (PCC) and paraganglioma. Moreover, there are no therapies that may prevent the onset or progression of tumors in patients with succinate dehydrogenase type B mutations, which are associated with very aggressive tumors. Therefore, we tested the approved and well-tolerated drugs lovastatin and 13-cis-retinoic acid (13cRA) in vitro in an aggressive PCC mouse cell line, mouse tumor tissue-derived (MTT) cells, and in vivo in a PCC allograft nude mouse model, in therapeutically relevant doses. Treatment was started 24 hours before sc tumor cell injection and continued for 30 more days. Tumor sizes were measured from outside by caliper and sizes of viable tumor mass by bioluminescence imaging. Lovastatin showed antiproliferative effects in vitro and led to significantly smaller tumor sizes in vivo compared with vehicle treatment. 13cRA promoted tumor cell growth in vitro and led to significantly larger viable tumor mass and significantly faster increase of viable tumor mass in vivo over time compared with vehicle, lovastatin, and combination treatment. However, when combined with lovastatin, 13cRA enhanced the antiproliferative effect of lovastatin in vivo. The combination-treated mice showed slowest tumor growth of all groups with significantly slower tumor growth compared with the vehicle-treated mice and significantly smaller tumor sizes. Moreover, the combination-treated group displayed the smallest size of viable tumor mass and the slowest increase in viable tumor mass over time of all groups, with a significant difference compared with the vehicle- and 13cRA-treated group. The combination-treated tumors showed highest extent of necrosis, lowest median microvessel density and highest expression of \u03b1-smooth muscle actin. The combination of high microvessel density and low \u03b1-smooth muscle actin is a predictor of poor prognosis in other tumor entities. Therefore, this drug combination may be a well-tolerated novel therapeutic or preventive option for malignant PCC.<\/jats:p>","DOI":"10.1210\/en.2014-1027","type":"journal-article","created":{"date-parts":[[2014,4,24]],"date-time":"2014-04-24T14:40:05Z","timestamp":1398350405000},"page":"2377-2390","source":"Crossref","is-referenced-by-count":18,"title":["Combination of 13-Cis Retinoic Acid and Lovastatin: Marked Antitumor Potential In Vivo in a Pheochromocytoma Allograft Model in Female Athymic Nude Mice"],"prefix":"10.1210","volume":"155","author":[{"given":"Svenja","family":"N\u00f6lting","sequence":"first","affiliation":[{"name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (S.N., A.Gi., Y.T., P.B., J.S., K.P.), National Institutes of Health, Bethesda, Maryland 20892"},{"name":"Department of Endocrinology (S.N., K.Y., M.K.), William Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University of London, London EC1M 6BQ, United Kingdom"},{"name":"Department of Internal Medicine II (S.N., B.G., G.V.), Campus Grosshadern, University-Hospital of the Ludwig-Maximilians-University of Munich, Munich 81377, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessio","family":"Giubellino","sequence":"first","affiliation":[{"name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (S.N., A.Gi., Y.T., P.B., J.S., K.P.), National Institutes of Health, Bethesda, Maryland 20892"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasin","family":"Tayem","sequence":"first","affiliation":[{"name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (S.N., A.Gi., Y.T., P.B., J.S., K.P.), National Institutes of Health, Bethesda, Maryland 20892"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Young","sequence":"first","affiliation":[{"name":"Department of Endocrinology (S.N., K.Y., M.K.), William Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University of London, London EC1M 6BQ, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Lauseker","sequence":"first","affiliation":[{"name":"Institute of Medical Informatics, Biometry, and Epidemiology (M.L.), University of Munich, Munich 81377, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"Bullova","sequence":"first","affiliation":[{"name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (S.N., A.Gi., Y.T., P.B., J.S., K.P.), National Institutes of Health, Bethesda, Maryland 20892"},{"name":"Department of Molecular Medicine (P.B.), Institute of Virology, Slovak Academy of Sciences, Bratislava 84505, Slovakia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Schovanek","sequence":"first","affiliation":[{"name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (S.N., A.Gi., Y.T., P.B., J.S., K.P.), National Institutes of Health, Bethesda, Maryland 20892"},{"name":"Department of Internal Medicine III (J.S.), Nephrology, Rheumatology, and Endocrinology, Faculty of Medicine and Dentistry, Palacky University, Olomouc 77520, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam","family":"Anver","sequence":"first","affiliation":[{"name":"Leidos Biomedical Research, Inc (M.A.), Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Fliedner","sequence":"first","affiliation":[{"name":"First Medical Department (S.F.), University Medical Center Schleswig-Holstein, Campus L\u00fcbeck, L\u00fcbeck 23538, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e1rta","family":"Korbonits","sequence":"first","affiliation":[{"name":"Department of Endocrinology (S.N., K.Y., M.K.), William Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University of London, London EC1M 6BQ, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Burkhard","family":"G\u00f6ke","sequence":"first","affiliation":[{"name":"Department of Internal Medicine II (S.N., B.G., G.V.), Campus Grosshadern, University-Hospital of the Ludwig-Maximilians-University of Munich, Munich 81377, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Vlotides","sequence":"first","affiliation":[{"name":"Department of Internal Medicine II (S.N., B.G., G.V.), Campus Grosshadern, University-Hospital of the Ludwig-Maximilians-University of Munich, Munich 81377, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley","family":"Grossman","sequence":"first","affiliation":[{"name":"Oxford Centre for Diabetes, Endocrinology and Metabolism (A.Gr.), University of Oxford, Oxford OX3 7LE, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karel","family":"Pacak","sequence":"first","affiliation":[{"name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (S.N., A.Gi., Y.T., P.B., J.S., K.P.), National Institutes of Health, Bethesda, Maryland 20892"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","reference":[{"issue":"1","key":"2020071613085812700_B1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s12022-012-9199-6","article-title":"Signaling pathways in pheochromocytomas and paragangliomas: prospects for future therapies","volume":"23","author":"N\u00f6lting","year":"2012","journal-title":"Endocr Pathol"},{"issue":"17","key":"2020071613085812700_B2","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1093\/jnci\/djt201","article-title":"Hypoxia-inducible factor signaling in pheochromocytoma: turning the rudder in the right direction","volume":"105","author":"Jochmanov\u00e1","year":"2013","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"2020071613085812700_B3","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1530\/JME-12-0028","article-title":"Combined blockade of signalling pathways shows marked anti-tumour potential in phaeochromocytoma cell lines","volume":"49","author":"N\u00f6lting","year":"2012","journal-title":"J Mol Endocrinol"},{"issue":"1","key":"2020071613085812700_B4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2012.04.011","article-title":"Statins and cancer: current and future prospects","volume":"324","author":"Osmak","year":"2012","journal-title":"Cancer Lett"},{"issue":"2","key":"2020071613085812700_B5","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00280-005-0013-8","article-title":"Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies","volume":"57","author":"Holstein","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"2020071613085812700_B6","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/ijc.24760","article-title":"In vivo evidence of duality effects for lovastatin in a nude mouse cancer model","volume":"126","author":"Wang","year":"2010","journal-title":"Int J Cancer"},{"issue":"10","key":"2020071613085812700_B7","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1093\/carcin\/bgh201","article-title":"Lovastatin inhibits tumor growth and lung metastasis in mouse mammary carcinoma model: a p53-independent mitochondrial-mediated apoptotic mechanism","volume":"25","author":"Shibata","year":"2004","journal-title":"Carcinogenesis"},{"issue":"9","key":"2020071613085812700_B8","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1093\/carcin\/15.9.2045","article-title":"Prevention of 1,2-dimethylhydrazine-induced colon tumorigenesis by HMG-CoA reductase inhibitors, pravastatin and simvastatin, in ICR mice","volume":"15","author":"Narisawa","year":"1994","journal-title":"Carcinogenesis"},{"issue":"4","key":"2020071613085812700_B9","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/bjc.1998.94","article-title":"Suppression by pravastatin, an inhibitor of p21ras isoprenylation, of hepatocarcinogenesis induced by N-nitrosomorpholine in Sprague-Dawley rats","volume":"77","author":"Tatsuta","year":"1998","journal-title":"Br J Cancer"},{"issue":"3","key":"2020071613085812700_B10","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1634\/theoncologist.11-3-306","article-title":"The role of statins in cancer therapy","volume":"11","author":"Hindler","year":"2006","journal-title":"Oncologist"},{"issue":"1","key":"2020071613085812700_B11","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.canlet.2009.06.022","article-title":"Statins potentiate cytostatic\/cytotoxic activity of sorafenib but not sunitinib against tumor cell lines in vitro","volume":"288","author":"Bil","year":"2010","journal-title":"Cancer Lett"},{"issue":"6","key":"2020071613085812700_B12","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1158\/1078-0432.CCR-04-1951","article-title":"Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor","volume":"11","author":"Mantha","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"14 pt 2","key":"2020071613085812700_B13","doi-asserted-by":"crossref","first-page":"4426s","DOI":"10.1158\/1078-0432.CCR-06-0089","article-title":"Strategies to enhance epidermal growth factor inhibition: targeting the mevalonate pathway 1","volume":"12","author":"Dimitroulakos","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2020071613085812700_B14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11060-008-9627-0","article-title":"Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status","volume":"90","author":"Cemeus","year":"2008","journal-title":"J Neurooncol"},{"issue":"6","key":"2020071613085812700_B15","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s10637-009-9319-4","article-title":"Lovastatin overcomes gefitinib resistance in human non-small cell lung cancer cells with K-Ras mutations","volume":"28","author":"Park","year":"2010","journal-title":"Invest New Drugs"},{"issue":"9","key":"2020071613085812700_B16","doi-asserted-by":"crossref","first-page":"e12563","DOI":"10.1371\/journal.pone.0012563","article-title":"Lovastatin inhibits VEGFR and AKT activation: synergistic cytotoxicity in combination with VEGFR inhibitors 1","volume":"5","author":"Zhao","year":"2010","journal-title":"PLoS One"},{"issue":"5","key":"2020071613085812700_B17","first-page":"1205","article-title":"Lovastatin enhances the antitumoral and apoptotic activity of doxorubicin in murine tumor models","volume":"19","author":"Rozados","year":"2008","journal-title":"Oncol Rep"},{"issue":"6","key":"2020071613085812700_B18","first-page":"576","article-title":"Statin use and reduced cancer-related mortality","volume":"368","author":"Nielsen","year":"2013","journal-title":"N Engl J Med"},{"issue":"2","key":"2020071613085812700_B19","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3109\/08923973.2010.521507","article-title":"All trans retinoic acid and cancer","volume":"33","author":"Siddikuzzaman","year":"2011","journal-title":"Immunopharmacol Immunotoxicol"},{"issue":"5","key":"2020071613085812700_B20","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S0889-8588(05)70256-2","article-title":"Retinoid therapy of childhood cancer","volume":"15","author":"Reynolds","year":"2001","journal-title":"Hematol Oncol Clin North Am"},{"issue":"2","key":"2020071613085812700_B21","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0045-6039(84)90038-1","article-title":"Retinoic acid-induced differentiation of cultured human neuroblastoma cells: a comparison with phorbolester-induced differentiation","volume":"14","author":"P\u00e5hlman","year":"1984","journal-title":"Cell Differ"},{"issue":"4","key":"2020071613085812700_B22","first-page":"589","article-title":"Retinoic acid-induced growth inhibition and morphologic differentiation of human neuroblastoma cells in vitro","volume":"68","author":"Sidell","year":"1982","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"2020071613085812700_B23","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1002\/(SICI)1097-0142(19981015)83:8<1471::AID-CNCR1>3.0.CO;2-6","article-title":"The emerging role of retinoids and retinoic acid metabolism blocking agents in the treatment of cancer","volume":"83","author":"Miller","year":"1998","journal-title":"Cancer"},{"issue":"16","key":"2020071613085812700_B24","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1056\/NEJM199910143411601","article-title":"Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children\u2019s Cancer Group","volume":"341","author":"Matthay","year":"1999","journal-title":"N Engl J Med"},{"issue":"2","key":"2020071613085812700_B25","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/jnci\/86.2.140","article-title":"Prevention of second primary tumors with isotretinoin in patients with squamous cell carcinoma of the head and neck: long-term follow-up","volume":"86","author":"Benner","year":"1994","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"2020071613085812700_B26","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJM199009203231205","article-title":"Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck","volume":"323","author":"Hong","year":"1990","journal-title":"N Engl J Med"},{"issue":"6","key":"2020071613085812700_B27","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/00001622-199911000-00011","article-title":"The biologic basis for the use of retinoids in cancer prevention and treatment","volume":"11","author":"Kurie","year":"1999","journal-title":"Curr Opin Oncol"},{"issue":"21","key":"2020071613085812700_B28","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1093\/jnci\/djm205","article-title":"Proliferative changes in the bronchial epithelium of former smokers treated with retinoids","volume":"99","author":"Hittelman","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"2020071613085812700_B29","first-page":"158","article-title":"Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications","volume":"7","author":"Dimitroulakos","year":"2001","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2020071613085812700_B30","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/1043-6618(95)80042-5","article-title":"Pharmacology of competitive inhibitors of HMG-CoA reductase","volume":"31","author":"Corsini","year":"1995","journal-title":"Pharmacol Res"},{"issue":"6","key":"2020071613085812700_B31","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/(SICI)1097-0215(19990611)81:6<970::AID-IJC21>3.0.CO;2-9","article-title":"Identification of a novel zinc finger gene, zf5-3, as a potential mediator of neuroblastoma differentiation","volume":"81","author":"Dimitroulakos","year":"1999","journal-title":"Int J Cancer"},{"issue":"3","key":"2020071613085812700_B32","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/nm0396-326","article-title":"HMG-CoA reductase mediates the biological effects of retinoic acid on human neuroblastoma cells: lovastatin specifically targets P-glycoprotein-expressing cells","volume":"2","author":"Dimitroulakos","year":"1996","journal-title":"Nat Med"},{"issue":"7","key":"2020071613085812700_B33","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/cbf.2830","article-title":"Isotretinoin treatment induces oxidative toxicity in blood of patients with acne vulgaris: a clinical pilot study","volume":"30","author":"Erturan","year":"2012","journal-title":"Cell Biochem Funct"},{"issue":"1\u20132","key":"2020071613085812700_B34","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11010-011-1045-5","article-title":"Simvastatin protects osteoblast against H2O2-induced oxidative damage via inhibiting the upregulation of Nox4","volume":"360","author":"Huang","year":"2012","journal-title":"Mol Cell Biochem"},{"issue":"4","key":"2020071613085812700_B35","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s11745-010-3517-x","article-title":"Simvastatin therapy reduces prooxidant-antioxidant balance: results of a placebo-controlled cross-over trial","volume":"46","author":"Parizadeh","year":"2011","journal-title":"Lipids"},{"issue":"8","key":"2020071613085812700_B36","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.4187\/respcare.00770","article-title":"Long-term simvastatin attenuates lung injury and oxidative stress in murine acute lung injury models induced by oleic acid and endotoxin","volume":"56","author":"Altintas","year":"2011","journal-title":"Respir Care"},{"issue":"4","key":"2020071613085812700_B37","first-page":"219","article-title":"Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man","volume":"50","author":"Freireich","year":"1966","journal-title":"Cancer Chemother Rep"},{"issue":"3","key":"2020071613085812700_B38","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s10585-009-9236-0","article-title":"Characterization of an animal model of aggressive metastatic pheochromocytoma linked to a specific gene signature","volume":"26","author":"Martiniova","year":"2009","journal-title":"Clin Exp Metastasis"},{"issue":"1","key":"2020071613085812700_B39","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.canlet.2011.10.019","article-title":"Characterization of two mouse models of metastatic pheochromocytoma using bioluminescence imaging","volume":"316","author":"Giubellino","year":"2012","journal-title":"Cancer Lett"},{"issue":"4","key":"2020071613085812700_B40","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/jso.2930310402","article-title":"Tumor measurement in the nude mouse","volume":"31","author":"Euhus","year":"1986","journal-title":"J Surg Oncol"},{"issue":"6","key":"2020071613085812700_B41","doi-asserted-by":"crossref","first-page":"e65624","DOI":"10.1371\/journal.pone.0065624","article-title":"Progenitor cell line (hPheo1) derived from a human pheochromocytoma tumor","volume":"8","author":"Ghayee","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"2020071613085812700_B42","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1001\/archotol.1989.01860280082021","article-title":"Vitamins A and E do protect against oral carcinoma","volume":"115","author":"Calhoun","year":"1989","journal-title":"Arch Otolaryngol Head Neck Surg"},{"issue":"10","key":"2020071613085812700_B43","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1001\/archotol.125.10.1083","article-title":"Biochemoprevention for dysplastic lesions of the upper aerodigestive tract","volume":"125","author":"Papadimitrakopoulou","year":"1999","journal-title":"Arch Otolaryngol Head Neck Surg"},{"issue":"4","key":"2020071613085812700_B44","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1001\/archotol.131.4.304","article-title":"Phase 2 bioadjuvant study of interferon alfa-2a, isotretinoin, and vitamin E in locally advanced squamous cell carcinoma of the head and neck: long-term follow-up","volume":"131","author":"Seixas-Silva","year":"2005","journal-title":"Arch Otolaryngol Head Neck Surg"},{"issue":"6","key":"2020071613085812700_B45","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/0002-9343(90)90215-Y","article-title":"Treatment with 13-cis-retinoic acid in transfusion-dependent patients with myelodysplastic syndrome and decreased toxicity with addition of \u03b1-tocopherol","volume":"89","author":"Besa","year":"1990","journal-title":"Am J Med"},{"issue":"1","key":"2020071613085812700_B46","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/RCT.0b013e318279abd1","article-title":"Necrosis degree displayed in computed tomography images correlated with hypoxia and angiogenesis in breast cancer","volume":"37","author":"Shan","year":"2013","journal-title":"J Comput Assist Tomogr"},{"issue":"8","key":"2020071613085812700_B47","doi-asserted-by":"crossref","first-page":"e71189","DOI":"10.1371\/journal.pone.0071189","article-title":"Intratumoral \u03b1-SMA enhances the prognostic potency of CD34 associated with maintenance of microvessel integrity in hepatocellular carcinoma and pancreatic cancer","volume":"8","author":"Wang","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"2020071613085812700_B48","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s11523-012-0216-y","article-title":"Imaging response in neuroendocrine tumors treated with targeted therapies: the experience of sunitinib","volume":"7","author":"Faivre","year":"2012","journal-title":"Target Oncol"}],"container-title":["Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/endo\/article-pdf\/155\/7\/2377\/10826262\/endo2377.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/endo\/article-pdf\/155\/7\/2377\/10826262\/endo2377.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T23:08:38Z","timestamp":1594940918000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/endo\/article\/155\/7\/2377\/2423197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,1]]},"references-count":48,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,7,1]]}},"URL":"https:\/\/doi.org\/10.1210\/en.2014-1027","relation":{},"ISSN":["0013-7227","1945-7170"],"issn-type":[{"value":"0013-7227","type":"print"},{"value":"1945-7170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,1]]}}}